Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Hydroxychloroquine + ADC in Advanced Breast Cancer
NCT06328387Phase 2Recruiting
- Sponsor
- Sun Yat-sen Memorial Hospital
- Start
- Jan 2024
- Primary completion
- Feb 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of hydroxychloroquine in breast cancer (4 arms), sponsored by Sun Yat-sen Memorial Hospital. Primary endpoints: Dose Limiting Toxicity at 3 weeks, Adverse Event at 2 years and 1 more. Started Jan 2024; status: recruiting.
02
Drugs
hydroxychloroquine
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT06328387.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06328387.